Acknowledging the limitations of observational studies and possible bias indicated by the complete case analysis, this study suggests that metformin, sulfonylureas, and insulin are associated with similar beneficial effects in patients with T2DM and HF of ischaemic aetiology. This evidence concerns the gene INS and type 2 diabetes mellitus.